09.11.18
Pfenex Inc. announced that Dr. Shawn A. Scranton, will be joining the company as its chief operating officer, effective October 1, 2018.
"As our operations have evolved through the advancement of our clinical pipeline and Pfenex is working towards its first NDA submission, we are increasing our focus on the approval and commercialization of our existing pipeline as well as exploration of new pipeline and technology opportunities. I am excited to announce the appointment of Dr. Shawn A. Scranton as Sr. Vice President and Chief Operating Officer, who will support this transition to a commercial stage biotech company," said Eef Schimmelpennink, chief executive officer of Pfenex. "Shawn brings more than 20 years of experience in the Biopharmaceutical industry, including a breadth of accomplishments in portfolio strategy, pharmaceutical research, clinical development, and commercial operations.”
Dr. Scranton previously served as chief scientific officer at Sentynl Therapeutics , Inc., a private specialty pharmaceutical company, recently acquired by Zydus Cadila.
"I am excited to join the Pfenex team at this important time in the Company’s development," said Dr. Scranton. "I look forward to working with the rest of the management team to execute upon its exciting pipeline of programs to generate significant stockholder value."
"As our operations have evolved through the advancement of our clinical pipeline and Pfenex is working towards its first NDA submission, we are increasing our focus on the approval and commercialization of our existing pipeline as well as exploration of new pipeline and technology opportunities. I am excited to announce the appointment of Dr. Shawn A. Scranton as Sr. Vice President and Chief Operating Officer, who will support this transition to a commercial stage biotech company," said Eef Schimmelpennink, chief executive officer of Pfenex. "Shawn brings more than 20 years of experience in the Biopharmaceutical industry, including a breadth of accomplishments in portfolio strategy, pharmaceutical research, clinical development, and commercial operations.”
Dr. Scranton previously served as chief scientific officer at Sentynl Therapeutics , Inc., a private specialty pharmaceutical company, recently acquired by Zydus Cadila.
